- Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).
- Amgen and Novartis have developed similar drugs aimed at treating heart conditions.
Novartis and Amgen stocks are declining, putting pressure on the Dow Jones Industrial Average due to their shared focus on cholesterol-targeting drugs.
1 report, 1 independent
Updated Sep 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Novartis and Amgen stocks are declining, putting pressure on the Dow Jones Industrial Average due to their shared focus on cholesterol-targeting drugs.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Novartis
Swiss-American multinational pharmaceutical corporation
-
Amgen
American multinational biopharmaceutical company
Related events
- Novartis's trial setbacks are negatively affecting market sentiment and causing a stock decline.
- The market is reacting to the news of Novartis' drug trial failures, specifically impacting Amgen's stock performance on the Nasdaq exchange.
- Novartis' drug failure has negatively impacted Amgen's financial outlook.
- Cantor Fitzgerald and other analyst firms issued ratings on Amgen stock, which is listed on the Nasdaq exchange.
- Novartis shares declined due to drug failure amidst geopolitical concerns regarding Iran and Oman, while Infineon benefited from an upgrade.